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Abstract: Gefitinib is the first epidermal growth factor receptor tyrosine-kinase inhibitor 
approved for the treatment of advanced non-small cell lung cancer (NSCLC). Its failure to 
improve survival in a placebo-control study, however, led to its withdrawal in the United States 
though it is available in many other countries Subsequent studies nevertheless showed comparable 
efficacy for gefitinib and docetaxel in the second-line therapy. Gefitinib significantly improved 
progression-free survival compared to chemotherapy in patients with activating mutations in 
the epidermal growth factor receptor tyrosine kinase mutations. This review will discuss the 
results of these large randomized studies and discuss the role of gefitinib in the treatment of 
advanced NSCLC.
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Introduction
Lung cancer is the most common cause of cancer mortality in the United States, with 
159,390 deaths estimated for the year 2009 by the American Cancer Society, accounting 
for 30% of cancer deaths in men and 26% of cancer deaths in women.1 Approximately 
87% of patients have one of the non-small cell lung cancer (NSCLC) histology sub-
types.2 The majority of patients present with locally advanced or metastatic disease,3 
and relapses are common in those undergoing resection with curative intent, even with 
the use of adjuvant chemotherapy.4 Treatment for patients with advanced disease is 
largely palliative, and the benefits appear to have reached a plateau with conventional 
platinum-based chemotherapy doublets.5 Inhibitors of epidermal growth factor receptor 
(EGFR) tyrosine kinase (TK) gefitinib and erlotinib are widely used in the treatment 
of advanced NSCLC. This review will focus on the role of gefitinib in the treatment 
of patients with advanced NSCLC.
EGFR is a transmembrane glycoprotein, consisting of three main components, 
including an extracellular ligand-binding domain, a transmembrane region, and a 
tyrosine kinase (TK) region. Binding of one of the ligands to the extracellular domain, 
including epidermal growth factor (EGF), transforming growth factor alpha (TGF-α), 
beta-cellulin, epiregulin and amphiregulin, leads to receptor dimerization and acti-
vation of the TK. The autophosphorylation triggered by the TK promotes multiple 
intracellular signaling pathways, ultimately causing cancer cell proliferation, invasion, 
and metastases.6 The EGFR pathway may be inhibited by a monoclonal antibody that 
prevents the ligand binding or by a small molecule that inhibits the TK activity.
Gefitinib is a low-molecular-weight, synthetic anilinoquinazoline compound that 
inhibits autophosphorylation and downstream signaling by reversibly binding to the Biologics: Targets & Therapy 2010:4 84
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ATP site. Initial pharmacokinetic studies in healthy male 
volunteers aged 18 to 62 years receiving escalating doses 
from 1 mg to 75 mg or 100 mg daily for 3 days, or evaluat-
ing the effect of food intake after a single dose of 50 mg, 
showed a peak plasma drug concentration (Cmax) between 3 
and 7 hours after administration, with a terminal elimination 
half-life of 28 hours.7 The Cmax was decreased by 34% with 
food ingestion, and the prolonged half-life suggested the 
feasibility of once daily administration. Overall, the treat-
ment was well tolerated, with a similar frequency of adverse 
effects compared to placebo.
Phase I clinical trials with gefitinib
The early experience with gefitinib in four open-label multi-
center phase I trials included patients with a variety of solid 
tumors known to have high expression of EGFR, such as 
NSCLC, breast, head and neck, colon, and ovarian tumors, 
although individual malignancies were not tested for base-
line EGFR.8–11 Treatment was overall well tolerated, with 
the most common adverse events including rash, diarrhea, 
nausea, anorexia, and asthenia. The lowest dose associated 
with tumor response was 150 mg daily, and the maximum 
tolerated dose was established at 700 mg daily. Given con-
cerns of sub-therapeutic dose administration in some patients 
due to pharmacokinetic variability, the lowest dose chosen 
for phase II clinical trials was 250 mg daily. The alternative 
dose of 500 mg daily was selected as the highest tolerated 
dose by most patients. Among the 100 patients with NSCLC 
enrolled in the combined 4 studies, 24 achieved stable disease 
and 10 had partial response.
Single-agent gefitinib in pretreated 
patients
The efficacy of gefitinib in NSCLC was evaluated in two mul-
ticenter phase II trials, the Iressa Dose Evaluation in Advanced 
Lung Cancer (IDEAL) studies I and II. Both studies were non-
placebo controlled and evaluated gefitinib at doses of 250 mg 
or 500 mg daily. The IDEAL-I trial, conducted in 43 centers 
worldwide, had approximately 50% of patients from Japan and 
enrolled patients who had one or two previous chemotherapy 
regimens, including a platinum-based combination.12 There 
were no significant differences for the dose of 250 mg compared 
to 500 mg, with similar response rates (18.4% versus 19%), 
disease control rate (54.4% versus 51.4%), progression-free 
survival (PFS) (2.7 months versus 2.8 months), median overall 
survival (7.6 months versus 8 months), and 1-year survival 
(35% versus 29%). Response rates were significantly better 
for Japanese patients compared to non-Japanese (27.5% versus 
10.4%; P = 0.002). The IDEAL-II trial was conducted in 30 
US centers and enrolled patients with advanced NSCLC and 
progressive disease after two or more regimens, including a 
platinum agent and docetaxel.13 Similar to IDEAL-I, there 
were no differences between the 250 mg and 500 mg daily 
doses according to response rates (12% versus 10%), median 
survival (7 months versus 6 months), and projected 1-year 
survival (27% versus 24%). Treatment was well tolerated in 
both studies, skin rash being the most common side effect. 
Since the efficacy was similar between the doses and toxicity 
was more frequent in patients receiving 500 mg, the lower dose 
became the standard. Clinical predictors for response included 
Japanese patients, women, adenocarcinoma histology, never 
smokers, and good performance status (0 or 1). Based on these 
results, gefitinib received accelerated Food and Drug Admin-
istration (FDA) approval on May 5, 2003, as monotherapy for 
the treatment of locally advanced or metastatic NSCLC after 
progression following treatment with platinum-based therapy 
and docetaxel.14
Following accelerated approval in the United States, the 
FDA mandated postmarketing trials for this agent to evalu-
ate its efficacy in prolonging survival in comparison to best 
supportive care. In the Iressa Survival Evaluation in Lung 
Cancer (ISEL) trial,15 a randomized phase III study enroll-
ing patients aged 18 or older, with advanced NSCLC previ-
ously treated with 1 or 2 previous regimens and refractory 
(progressive disease within 90 days from the last treatment 
dose) or intolerant to the last treatment, were randomized to 
gefitinib 250 mg daily or placebo in a ratio of 2 to 1. A total 
of 1692 eligible patients were accrued from 28 countries 
worldwide. The groups were well balanced, 50% received at 
least 2 prior chemotherapies, and 90% of the patients were 
refractory to the last chemotherapy. After a median follow-
up of 7.2 months, there was no significant benefit for gefitinib 
compared to placebo according to median survival (5.6 months 
versus 5.1 months) or estimated 1-year survival (27% versus 
21%) (hazard ratio [HR] 0.89, 95% confidence interval [CI] 
0.77–1.02; P = 0.087). Similarly, despite numerically superior 
median survival (6.3 months versus 5.4 months) and 1-year 
survival (30% versus 18%), the benefit from gefitinib did not 
reach statistical significance compared to best supportive care 
in patients with adenocarcinoma (HR 0.84; 95% CI 0.68–1.03; 
P = 0.089). Although the primary analysis by log rank test did 
not show survival benefit for the gefitinib arm, the preplanned 
supportive Cox’s regression analysis, with covariate adjustments 
identical to the log rank test, showed a statistically significant 
improvement for gefitinib compared to placebo in both over-
all population (P = 0.03) and adenocarcinoma (P = 0.033). Biologics: Targets & Therapy 2010:4 85
Gefitinib for NSCLC Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Additional pre-planned analyses showed better survival for 
gefitinib compared to placebo in non-smokers (8.9 months 
versus 6.1 months; P = 0.012) and Asians (9.5 months versus 
5.5 months, P = 0.01). On December 17, 2004, AstraZeneca 
issued a letter to US physicians reporting the lack of survival 
improvement for gefitinib, urging them to consider other treat-
ment options.16 Gefitinib was essentially replaced by erlotinib 
after the results of the BR.21 study,17 a randomized phase 
III trial showing improved survival for second-line erlotinib 
compared to placebo. Although only the erlotinib trial showed 
a statistically significant survival improvement over placebo, 
there were similar response rates (8% versus 8.9%), stable 
disease (32% versus 35%), and 1-year survival (27% versus 
31%) for gefitinib and erlotinib, respectively. 
Second-line gefitinib compared  
to chemotherapy
Four recent studies compared gefitinib 250 mg daily with 
docetaxel (60–75 mg/m2 every 3 weeks) in patients with 
advanced NSCLC (Table 1). The Second-line Indication 
of Gefitinib in NSCLC (SIGN) trial was an international 
multicenter trial comparing gefitinib to docetaxel in patients 
with advanced NSCLC progressing through one previous 
line of chemotherapy.18 Between October 2003 and June 
2004, 68 patients were randomized to gefitinib and 73 
to docetaxel. Response rates, median PFS, and median 
survival for gefitinib and docetaxel were 13.2% and 13.7%, 
3 months and 3.4 months, and 7.5 months and 7.1 months, 
respectively. Gefitinib was associated with fewer adverse 
events overall (51.5% versus 78.9%) and grade 3 or 4 toxicity 
(8.8% versus 25.4%). The Iressa as a Second-line Therapy 
in Advanced NSCLC (ISTANA) was a multicenter Korean 
study that enrolled 82 patients to gefitinib and 79 patients 
to docetaxel.19 Response rates for gefitinib were signifi-
cantly higher compared to docetaxel (28.1% versus 7.6%; 
P  0.001). Gefitinib was also associated with increased PFS 
(P = 0.044), and the overall survival results are still pending. 
The V-15-32 study was a multicenter Japanese study enroll-
ing patients with advanced NSCLC previously treated with 
one or two lines of chemotherapy.20 Between September 
2003 and January 2006, 245 patients were enrolled into the 
gefitinib arm and 244 to docetaxel. Response rates were 
significantly superior for the gefitinib arm (22.5% versus 
12.8% (OR 2.14; 95% CI 1.21–3.78, P = 0.009), median 
PFS was identical in both arms (2 months),and median 
survival and 1-year survival for gefitinib and docetaxel 
were 11.5 months and 47.8% and 14 months and 53.7%, 
respectively. Although there were no statistically significant 
differences in overall survival (P = 0.33), the predefined cri-
terion for non-inferiority (upper CI limit for HR  1.25) was 
not achieved (HR 1.12; 95.24% CI 0.89–1.40). Nevertheless, 
despite the lack of proven non-inferiority, the similar survival 
and decreased toxicity for gefitinib showed that this agent 
remained an effective therapy. The Iressa NSCLC Trial Evalu-
ating Response and Survival versus Taxotere (INTEREST) 
was a multicenter randomized phase III trial enrolling patients 
with advanced NSCLC who had been previously treated 
with a platinum-based chemotherapy.21 In this large study, 
733 patients received gefitinib and 733 received docetaxel. 
Compared to docetaxel, gefitinib was associated with similar 
response rates (9.1% versus 7.6%; OR 1.22, P = 0.33), PFS 
(2.2 months versus 2.7 months; HR 1.04, P = 0.47), and 
median overall survival (7.6 months versus 8 months; HR 
1.020; 95% CI 0.905–1.150). This study, unlike the V-15-32, 
met the predefined non-inferiority criterion, which was deter-
mined as the upper confidence limit 1.154. Subset analyses 
showed longer survival for never smokers, women, Asian 
patients, and those with adenocarcinoma, but this survival 
Table 1 Recent studies comparing gefitinib 250 mg daily with docetaxel (60–75 mg/m2 every 3 weeks) in patients with advanced NSCLC
Trial (year) Treatment Patients Response (%) Median PFS (months) Median OS (months)
SIGN (2005)18 Gefitinib 68 13.2 3 7.5
Docetaxela 73 13.7 3.4 7.1
ISTANA (2008)19 Gefitinib 82 28.1% Nr Nr
Docetaxela 79 7.6% Nr Nr
V-15-32 (2008)20 Gefitinib 245 22.5 2 11.5
Docetaxelb 244 12.8 2 14
INTEREST (2008)21 Gefitinib 733 9.1 2.2 7.6
Docetaxela 733 7.6 2.7 8
aDocetaxel 75 mg/m2
bDocetaxel 60 mg/m2
Abbreviations: PFS, progression-free survival; OS, overall survival; Nr, not reported.Biologics: Targets & Therapy 2010:4 86
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prolongation compared to their counterparts was observed in 
both the gefitinib and docetaxel arms compared to the rest of 
the population. Similar to the other reported trials, toxicity 
was significantly lower in the gefitinib arm.
Shepherd and colleagues recently reported the meta-
analysis of the four clinical trials comparing gefitinib 
with docetaxel.22 In univariate analysis, gefitinib was 
associated with increased response rates (OR 1.65; 95% 
CI 1.24–2.21, P = 0.0007) but similar PFS (HR 0.96; 95% CI 
0.87–1.05, P = 0.37) and overall survival (HR 1.03; 95% CI 
0.93–1.13, P = 0.57). When adjusted for study, smoking his-
tory, number of previous chemotherapy regimens, response to 
prior therapy, gender, age, and performance status, response 
rates remained significantly better for gefitinib (OR 1.58; 
95% CI 1.19–2.10, P = 0.001), whereas PFS and overall 
survival were similar. Taken together, the current data suggest 
that in the second line setting, gefitinib had similar efficacy 
as docetaxel but was better tolerated even in molecularly 
unselected patients with advanced NSCLC.
Experience with first-line gefitinib  
in unselected patients
Multiple trials have evaluated the use of gefitinib in previously 
untreated advanced unselected NSCLC patients (Table 2). 
Reck and colleagues23 showed a 5% response rate with 40% 
stable disease in 58 patients. Median PFS and survival were 
7 weeks and 29 weeks, respectively. In contrast, Niho and col-
leagues24 showed response rate of 30% in 40 eligible patients, 
with median survival of 13.9 months and 1-year survival of 
55%. Nevertheless, despite encouraging response rates and 
survival, 4 patients (10%) developed interstitial lung disease, 
which was considered unacceptable, particularly in the first-
line setting. The Iressa in NSCLC versus Vinorelbine Investi-
gation in The Elderly (INVITE) was a multicenter randomized 
phase II trial comparing gefitinib to vinorelbine 30 mg/m2 on 
days 1 and 8 every 21 days in patients aged 70 or older with 
chemotherapy-naïve advanced NSCLC.25 The median PFS, 
the primary objective of the study, was 2.7 months in patients 
treated with gefitinib and 2.9 months in those treated with 
vinorelbine (HR 1.19, 95% CI 0.85–1.65, P = 0.31). Median 
overall survival for gefitinib and vinorelbine were 5.9 months 
and 8 months, respectively (HR 0.98; 95% CI 0.66–1.47). 
Treatment was better tolerated in the gefitinib arm. Two large 
phase III trials evaluated the role of gefitinib in combination 
to chemotherapy compared to chemotherapy alone in previ-
ously untreated patients with advanced NSCLC. In both the 
Iressa NSCLC Trial Accessing the Combination Treatment 
(INTACT)-1 trial,26 in which the control arm included cisplatin 
and gemcitabine, and the INTACT-2 trial,27 with carboplatin 
and paclitaxel, the addition of gefitinib failed to improve 
response rates, PFS, median survival time, or 1-year survival. 
In a subset analysis of patients in the INTACT-2 study with 
adenocarcinoma and receiving treatment for 90 or more days, 
the median survival for patients in the low-dose gefitinib 
arm (250 mg day) was significantly higher than placebo 
(17.1 months versus 13.6 months, P = 0.05). These findings 
suggest that sequential therapy with chemotherapy followed by 
gefitinib, rather than concurrent, may be the optimal schedule, 
and there could be a role for maintenance gefitinib.
In the phase III West Japan Thoracic Oncology Group 
0203, chemotherapy naive patients with advanced NSCLC 
were randomized to receive either platinum doublet for up 
to 6 cycles or 3 cycles of the same chemotherapy followed 
by gefitinib daily until disease progression.28 Although there 
was an improvement in the PFS for patients treated with 
maintenance gefintinib (4.6 versus 4.2 months, P  0.001), 
overall survival, the primary endpoint did not reach statisti-
cal significance (13.6 versus 12.8 months, P = 0.10). In the 
Table 2 First-line gefitinib in advanced NSCLC 
Trial/author (year) Phase Treatment Patients Response (%) Median PFS/TTP (months) Median OS (months)
Reck (2006)23 ii Gefitinib 58 5 1.7 6.7
Niho (2006)24 ii Gefitinib 40 30 NA 13.9
INVITE (2008)25 iii Gefitinib 97 3.1 2.7 5.9
Vinorelbine 99 5.1 2.9 8
INTACT-1 (2004)26 iii CpGm 324 47.2 6 10.9
CpGmGefitinib 250 336 51.2 5.8 9.9
CpGmGefitinib 500 330 50.3 5.5 9.9
INTACT-2 (2004)27 iii CbPc 345 30 5 9.9
CbPcGefitinib 250 345 30.4 5.3 9.8
CbPcGefitinib 500  347 28.7 4.6 8.7
Abbreviations: Cb, carboplatin; Cp, cisplatin; Gm, gemcitabine; Pc, paclitaxel; PFS, progression-free survival; TTP, time to progression; Nr, not reported.Biologics: Targets & Therapy 2010:4 87
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subset of patients with adenocarcinoma however, the gefitinib 
use was associated with better overall survival (15.4 versus 
14.3 months, P = 0.03).
Patient selection for gefitinib
Since initial trials showed improved responses in never 
smokers, patients with EGFR mutation, and bronchioloal-
veolar histology (BAC), subsequent studies were developed 
for these specific patient populations (Table 3).
In the multicenter phase II ONCOBELL study29 enroll-
ing patients who were never smokers or had EGFR positive 
by fluorescence in situ hybridization (FISH) and p-AKT 
positive irrespective of smoking status, the response rate 
and 1-year survival in the 42 available patients were 48% 
and 64% respectively.
In the randomized phase III Iressa Pan-Asia Study 
(IPASS), previously untreated patients with adenocarcinoma 
and history of smoking either less than 100 cigarettes in 
their lifetime (non-smokers) or 10 pack-year or less quit-
ting tobacco for at least 15 years (former light smokers) 
were randomize to receive first-line gefitinib 250 mg daily 
or carboplatin plus paclitaxel.30 Response rates were higher 
for the gefitinib arm in both the overall population (43% 
versus 33%, P  0.001) and in patients with EGFR muta-
tion (71.2% versus 47.3%, P  0.001%). In contrast, the 
response rate was significantly lower for gefitinib compared to 
chemotherapy in patients without the EGFR mutation (1.1% 
versus 23.5%, P = 0.001). PFS in patients receiving gefitinib 
was significantly improved in those with EGFR mutation 
(HR for progression 0.48; 95% CI, 0.36–0.64; P  0.001) 
but significantly worse in those without the mutation (HR 
1.85; 95% CI 2.05–3.98; P  0.001). Significant response 
rates and survival were also observed in a Korean study, 
where 55% of the 72 patients achieved survival and 76% 
were alive at 1 year.31
The two studies evaluating the role of single agent gefi-
tinib in patients with BAC showed response rates of 13% 
to 17%, median survival of 13 to 13.3 months, and 1-year 
survival rates of 51 to 55%.32,33
In addition to clinical correlates, such as ethnicity, gender, 
histology, and smoking status, several molecular features 
that are associated with response to EGFR TKIs have been 
reported. The first predictor for response discovered was the 
activating EGFR mutations in a small region of the EGFR 
gene encoding the tyrosine kinase domain.34,35 The most 
common of these mutations are an in-frame deletion of 
exon 19 and a missense mutation at codon 858 resulting in 
arginine–leucine substitution (L858R). Several studies showed 
significant improvement in response rates among patients with 
activating EGFR gene mutation treated with gefitinib. Small 
trials, mostly from Japan and enrolling between 16 and 28 
patients with EGFR mutation, showed response rates ranging 
from 50% to 90%, and PFS from 7.7 months to 13 months.36–40 
In the two studies reporting 1-year survival, it ranged between 
79% and 88%. In the larger, predominantly non-Asian, 
iTARGET study,41 the response rate and 1-year survival for 
patients NSCLC harboring the EGFR mutation and treated 
with first-line gefitinib were 55% and 73% respectively.
EGFR gene amplification has also been associated with 
response to gefitinib. The EGFR gene is located in the chro-
mosome 7 and may be detected by FISH. Cappuzzo and 
colleagues42 showed that true gene amplification by FISH in 
Table 3 Single-agent gefitinib in selected patients
Study/author  
(year)
Setting Patients Response (%) PFS/TTP  
(months)
Median survival  
(months)
1-year survival
ONCOBELL (2007)29 Never-smokersa 42 48 6.4 Nr 64
Lee (2006)31 Never-smokers 55 61 6.5 Nr 79
iTARGET (2008)41 eGFr mutation 31 55 9.2 17.5 73
Asahina (2006)36 eGFr mutation 16 75 8.9 Nr 88
ONCOBELL (2007)29 eGFr mutation 42 48 6.4 Nr 64
Inoue (2006)37 eGFr mutation 16 75 9.7 Nr Nr
Sutani (2006)38 eGFr mutation 27 78 9.4 15.4 Nr
Sunaga (2007)39 eGFr mutation 19 84 13 Nr Nr
Tamura (2008)40 eGFr mutation 28 75 11.5 Nr 79
West (2006)32 BAC 101 17 4 13 51
Cadranel (2007)33 BAC 88 13 2.9 13.3 55
aPatients were also enrolled if they had eGFr and p-AKT mutations regardless of smoking status.
Abbreviations: eGFr, epidermal growth factor receptor; PFS, progression-free survival; TTP, time to progression; Nr, not reported; BAC, bronchioloalveolar carcinoma.Biologics: Targets & Therapy 2010:4 88
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patients treated with gefitinib (tight EGFR genes clusters and 
a ratio of EGFR gene to chromosome 2, or 15 copies of 
EGFR per cell in 10 or more of the analyzed cells), or high 
polysomy (4 copies in 40% of cells) were associated with 
improved response rates (36% versus 3%, P  0.001), time 
to progression (9 versus 2.2 months, P  0.001) and median 
survival (18.7 versus 10.3 months, P = 0.03) compared to 
those without these features. In Oncobell study,29 patients 
with EGFR FISH positive status had response rates of 68% 
(vs 9.1% in EGFR FISH negative) and TTP of 7.6 months 
(vs 2.7 months in EGFR FISH negative). In the retrospec-
tive analysis of the ISEL study,15 survival patients treated 
with gefitinib was improved compared to placebo in patients 
with EGFR amplification by FISH (8.3 versus 4.5 months, 
P = 0.067) and decreased in those low EGFR gene copy (4.3 
versus 6.2 months, P = 0.417).43 These results contrast to the 
In the INTEREST trial,21 where there was no benefit from 
the use of gefitinib, compared to docetaxel in patients with 
EGFR mutation.
Polymorphisms related to the EGFR pathway have been 
studied to predict response to EGFR TKIs. The intron 1 CA 
repeat polymorphism has been most studied. Shorter CA 
repeats are associated with higher response rates and survival 
in patients treated with EGFR TKIs.44,45
K-ras mutations, which are mutually exclusive with 
EGFR mutations in lung cancer, are most commonly seen 
in smokers and associated with resistance to gefitinib. 
Among multiple studies evaluating the use of gefitinib 
or erlotinib in patients with K-ras mutations, mutations 
were found in approximately 17% of patients by pooled 
analysis, with most trials showed no response to TKIs.46 
Although K-ras mutations have been strongly associated 
with cigarette smoking, a recent study on 482 lung adeno-
carcinomas showed the presence of K-ras mutations 15% 
of never smokers, 22% of former smokers, and 25% of 
current smokers.47
Summary
Despite the withdrawal of gefitinib in the United States after 
the results from the ISEL study,15 gefitinib continues to be 
evaluated in multiple studies and has been shown to have 
comparable efficacy to standard chemotherapy in the second-
line setting. Gefitinib produces stellar and striking results in 
patients with lung cancer whose tumor cells harbor activating 
mutations in EGFR TK domain and has now been approved 
for use in Europe in this molecularly selected population.
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